Morgan Stanley’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $30.1M | Sell |
3,432,678
-586,191
| -15% | -$4.44M | ﹤0.01% | 2721 |
|
|
2026
Q1 | $30.8M | Sell |
4,018,869
-1,087,345
| -21% | -$7.44M | ﹤0.01% | 2558 |
|
|
2025
Q4 | $10.1M | Buy |
5,106,214
+1,732,644
| +51% | +$3.93M | ﹤0.01% | 3604 |
|
|
2025
Q3 | $8.3M | Buy |
3,373,570
+401,301
| +14% | +$1.03M | ﹤0.01% | 3699 |
|
|
2025
Q2 | $7.85M | Buy |
2,972,269
+1,077,135
| +57% | +$2.9M | ﹤0.01% | 3675 |
|
|
2025
Q1 | $5.7M | Sell |
1,895,134
-2,110,680
| -53% | -$6.4M | ﹤0.01% | 3815 |
|
|
2024
Q4 | $10.3M | Buy |
4,005,814
+1,758,922
| +78% | +$7.33M | ﹤0.01% | 3389 |
|
|
2024
Q3 | $8.36M | Buy |
2,246,892
+1,678,491
| +295% | +$7.77M | ﹤0.01% | 3561 |
|
|
2024
Q2 | $3.59M | Sell |
568,401
-56,200
| -9% | -$371K | ﹤0.01% | 4152 |
|
|
2024
Q1 | $3.35M | Buy |
624,601
+24,883
| +4% | +$113K | ﹤0.01% | 4225 |
|
|
2023
Q4 | $3.01M | Buy |
599,718
+201,817
| +51% | +$633K | ﹤0.01% | 4265 |
|
|
2023
Q3 | $672K | Buy |
397,901
+47,254
| +13% | +$94.9K | ﹤0.01% | 5013 |
|
|
2023
Q2 | $975K | Sell |
350,647
-223,119
| -39% | -$631K | ﹤0.01% | 4847 |
|
|
2023
Q1 | $1.04M | Buy |
573,766
+29,608
| +5% | +$92.1K | ﹤0.01% | 4832 |
|
|
2022
Q4 | $2.76M | Sell |
544,158
-97,655
| -15% | -$536K | ﹤0.01% | 4241 |
|
|
2022
Q3 | $3.19M | Sell |
641,813
-336,830
| -34% | -$1.53M | ﹤0.01% | 4055 |
|
|
2022
Q2 | $3.64M | Sell |
978,643
-94,876
| -9% | -$381K | ﹤0.01% | 4032 |
|
|
2022
Q1 | $6.02M | Buy |
1,073,519
+640,695
| +148% | +$3.93M | ﹤0.01% | 3479 |
|
|
2021
Q4 | $2.63M | Sell |
432,824
-64,900
| -13% | -$488K | ﹤0.01% | 4352 |
|
|
2021
Q3 | $4.85M | Buy |
497,724
+9,434
| +2% | +$104K | ﹤0.01% | 3743 |
|
|
2021
Q2 | $6.97M | Buy |
488,290
+155,215
| +47% | +$2.56M | ﹤0.01% | 3419 |
|
|
2021
Q1 | $7.91M | Buy |
333,075
+13,186
| +4% | +$342K | ﹤0.01% | 2901 |
|
|
2020
Q4 | $4.26M | Buy |
319,889
+63,462
| +25% | +$610K | ﹤0.01% | 3426 |
|
|
2020
Q3 | $1.78M | Sell |
256,427
-26,053
| -9% | -$260K | ﹤0.01% | 3762 |
|
|
2020
Q2 | $3.47M | Buy |
282,480
+216,945
| +331% | +$1.22M | ﹤0.01% | 3050 |
|
|
2020
Q1 | $189K | Buy |
65,535
+55,428
| +548% | +$278K | ﹤0.01% | 4889 |
|
|
2019
Q4 | $38K | Buy |
10,107
+173
| +2% | +$294 | ﹤0.01% | 5935 |
|
|
2019
Q3 | $12K | Sell |
9,934
-38,563
| -80% | -$47.8K | ﹤0.01% | 6147 |
|
|
2019
Q2 | $50K | Buy |
48,497
+36,486
| +304% | +$42.1K | ﹤0.01% | 5603 |
|
|
2019
Q1 | $19K | Sell |
12,011
-53,198
| -82% | -$66.8K | ﹤0.01% | 6021 |
|
|
2018
Q4 | $76K | Sell |
65,209
-39,193
| -38% | -$89.7K | ﹤0.01% | 5642 |
|
|
2018
Q3 | $385K | Sell |
104,402
-115,999
| -53% | -$367K | ﹤0.01% | 5136 |
|
|
2018
Q2 | $674K | Buy |
220,401
+23,206
| +12% | +$85.9K | ﹤0.01% | 4894 |
|
|
2018
Q1 | $767K | Buy |
197,195
+88,590
| +82% | +$388K | ﹤0.01% | 4734 |
|
|
2017
Q4 | $488K | Buy |
108,605
+46,425
| +75% | +$220K | ﹤0.01% | 4992 |
|
|
2017
Q3 | $341K | Buy |
62,180
+24,886
| +67% | +$153K | ﹤0.01% | 5094 |
|
|
2017
Q2 | $282K | Buy |
37,294
+1,664
| +5% | +$7.19K | ﹤0.01% | 5145 |
|
|
2017
Q1 | $127K | Sell |
35,630
-32,814
| -48% | -$162K | ﹤0.01% | 5510 |
|
|
2016
Q4 | $392K | Buy |
68,444
+48,958
| +251% | +$327K | ﹤0.01% | 5061 |
|
|
2016
Q3 | $151K | Sell |
19,486
-6,681
| -26% | -$49.9K | ﹤0.01% | 5130 |
|
|
2016
Q2 | $163K | Buy |
26,167
+10,619
| +68% | +$82.4K | ﹤0.01% | 5032 |
|
|
2016
Q1 | $128K | Buy |
15,548
+8,842
| +132% | +$83.3K | ﹤0.01% | 5197 |
|
|
2015
Q4 | $117K | Sell |
6,706
-132,279
| -95% | -$1.96M | ﹤0.01% | 5323 |
|
|
2015
Q3 | $1.59M | Buy |
+138,985
| New | +$3.03M | ﹤0.01% | 3716 |
|
Other funds holding IBRX
Morgan Stanley's IBRX Position: Q2 2026 in Review
Morgan Stanley reduced its ImmunityBio (IBRX) stake by 15% in Q2 2026, selling an estimated $4.44M and leaving 3,432,678 shares worth $30.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2721.
Morgan Stanley first reported a position in IBRX in Q3 2015 and has held it in 44 quarters since. The position peaked at $30.8M in Q1 2026. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.
- Morgan Stanley held 3,432,678 shares of ImmunityBio worth $30.1M as of Q2 2026.
- Morgan Stanley sold 586,191 ImmunityBio shares in Q2 2026, an estimated $4.44M.
- ImmunityBio made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2721 holding.
- Morgan Stanley first reported a position in ImmunityBio in Q3 2015 and has held it in 44 quarters since.
- Morgan Stanley's ImmunityBio position peaked at $30.8M in Q1 2026.
- 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.